hero image

Biogen Idec Announces Preliminary Tabulation of Stockholder Vote by Independent Inspector of Elections

June 9, 2009 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) today announced that, based on a preliminary tabulation by the independent inspector of elections, IVS Associates, Robert W. Pangia, William D. Young, Alexander J. Denner and Richard C. Mulligan have been elected to the Company’s Board of Directors. Their terms take effect upon final certification of the results of the stockholder vote by IVS Associates.

The Company also announced that the preliminary tabulation by IVS Associates confirms stockholders voted to institute majority voting in uncontested elections, ratify the Company’s auditor, and reject proposals to change the Company’s jurisdiction of incorporation to North Dakota and set the size of the Board at 13.

Bruce R. Ross, Biogen Idec’s Chairman, said, “We welcome Alexander Denner and Richard Mulligan to the Board and look forward to working with them to build on Biogen Idec’s strong track record of delivering value.”

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

 

Biogen Idec Media Contact:
Jennifer Neiman, 617-914-6524
Senior Manager, Public Affairs
or
Biogen Idec Investor Relations Contact:
Eric Hoffman, 617-679-2812
Director, Investor Relations

thumb
April 24, 2024
BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2024 financial results Wednesday, April 24, 2024, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

thumb
March 31, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

TOKYO and CAMBRIDGE, Mass., April 1, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai submitted to the U.S.